365 related articles for article (PubMed ID: 25115638)
1. PI3K/Akt/mTOR signaling in medullary thyroid cancer: a promising molecular target for cancer therapy.
Manfredi GI; Dicitore A; Gaudenzi G; Caraglia M; Persani L; Vitale G
Endocrine; 2015 Mar; 48(2):363-70. PubMed ID: 25115638
[TBL] [Abstract][Full Text] [Related]
2. Novel withanolides target medullary thyroid cancer through inhibition of both RET phosphorylation and the mammalian target of rapamycin pathway.
Samadi AK; Bazzill J; Zhang X; Gallagher R; Zhang H; Gollapudi R; Kindscher K; Timmermann B; Cohen MS
Surgery; 2012 Dec; 152(6):1238-47. PubMed ID: 23158190
[TBL] [Abstract][Full Text] [Related]
3. Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.
Jin N; Jiang T; Rosen DM; Nelkin BD; Ball DW
Clin Cancer Res; 2011 Oct; 17(20):6482-9. PubMed ID: 21831957
[TBL] [Abstract][Full Text] [Related]
4. Resveratrol potentiates the anti-tumor effects of rapamycin in papillary thyroid cancer: PI3K/AKT/mTOR pathway involved.
Bian P; Hu W; Liu C; Li L
Arch Biochem Biophys; 2020 Aug; 689():108461. PubMed ID: 32531316
[TBL] [Abstract][Full Text] [Related]
5. Targeting the PI3-kinase/Akt/mTOR signaling pathway.
Hassan B; Akcakanat A; Holder AM; Meric-Bernstam F
Surg Oncol Clin N Am; 2013 Oct; 22(4):641-64. PubMed ID: 24012393
[TBL] [Abstract][Full Text] [Related]
6. The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients.
Martelli AM; Evangelisti C; Chiarini F; McCubrey JA
Oncotarget; 2010 Jun; 1(2):89-103. PubMed ID: 20671809
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory Potential of Dietary Nutraceuticals on Cellular PI3K/Akt Signaling: Implications in Cancer Prevention and Therapy.
Narayanankutty A
Curr Top Med Chem; 2021; 21(20):1816-1831. PubMed ID: 34279200
[TBL] [Abstract][Full Text] [Related]
8. Targeting the PI3K/Akt/mTOR pathway for breast cancer therapy.
Cidado J; Park BH
J Mammary Gland Biol Neoplasia; 2012 Dec; 17(3-4):205-16. PubMed ID: 22865098
[TBL] [Abstract][Full Text] [Related]
9. The Current Status and Future Role of the Phosphoinositide 3 Kinase/AKT Signaling Pathway in Urothelial Cancer: An Old Pathway in the New Immunotherapy Era.
Liu ST; Hui G; Mathis C; Chamie K; Pantuck AJ; Drakaki A
Clin Genitourin Cancer; 2018 Apr; 16(2):e269-e276. PubMed ID: 29199023
[TBL] [Abstract][Full Text] [Related]
10. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
Polivka J; Janku F
Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
[TBL] [Abstract][Full Text] [Related]
11. Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor.
Zou CY; Smith KD; Zhu QS; Liu J; McCutcheon IE; Slopis JM; Meric-Bernstam F; Peng Z; Bornmann WG; Mills GB; Lazar AJ; Pollock RE; Lev D
Mol Cancer Ther; 2009 May; 8(5):1157-68. PubMed ID: 19417153
[TBL] [Abstract][Full Text] [Related]
12. Targeting the PI3K/Akt/mTOR pathway in malignancy: rationale and clinical outlook.
Cho DC
BioDrugs; 2014 Aug; 28(4):373-81. PubMed ID: 24567265
[TBL] [Abstract][Full Text] [Related]
13. Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer.
Hernandez-Aya LF; Gonzalez-Angulo AM
Oncologist; 2011; 16(4):404-14. PubMed ID: 21406469
[TBL] [Abstract][Full Text] [Related]
14. Activation of the mTOR pathway in primary medullary thyroid carcinoma and lymph node metastases.
Tamburrino A; Molinolo AA; Salerno P; Chernock RD; Raffeld M; Xi L; Gutkind JS; Moley JF; Wells SA; Santoro M
Clin Cancer Res; 2012 Jul; 18(13):3532-40. PubMed ID: 22753663
[TBL] [Abstract][Full Text] [Related]
15. The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer.
Mabuchi S; Kuroda H; Takahashi R; Sasano T
Gynecol Oncol; 2015 Apr; 137(1):173-9. PubMed ID: 25677064
[TBL] [Abstract][Full Text] [Related]
16. Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations.
Ganesan P; Janku F; Naing A; Hong DS; Tsimberidou AM; Falchook GS; Wheler JJ; Piha-Paul SA; Fu S; Stepanek VM; Lee JJ; Luthra R; Overman MJ; Kopetz ES; Wolff RA; Kurzrock R
Mol Cancer Ther; 2013 Dec; 12(12):2857-63. PubMed ID: 24092809
[TBL] [Abstract][Full Text] [Related]
17. Novel approaches for molecular targeted therapy of breast cancer: interfering with PI3K/AKT/mTOR signaling.
Grunt TW; Mariani GL
Curr Cancer Drug Targets; 2013 Feb; 13(2):188-204. PubMed ID: 23215720
[TBL] [Abstract][Full Text] [Related]
18. Metformin inhibits growth and decreases resistance to anoikis in medullary thyroid cancer cells.
Klubo-Gwiezdzinska J; Jensen K; Costello J; Patel A; Hoperia V; Bauer A; Burman KD; Wartofsky L; Vasko V
Endocr Relat Cancer; 2012 Jun; 19(3):447-56. PubMed ID: 22389381
[TBL] [Abstract][Full Text] [Related]
19. Targeting PI3K/AKT/mTOR network for treatment of leukemia.
Bertacchini J; Heidari N; Mediani L; Capitani S; Shahjahani M; Ahmadzadeh A; Saki N
Cell Mol Life Sci; 2015 Jun; 72(12):2337-47. PubMed ID: 25712020
[TBL] [Abstract][Full Text] [Related]
20. Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance.
Ediriweera MK; Tennekoon KH; Samarakoon SR
Semin Cancer Biol; 2019 Dec; 59():147-160. PubMed ID: 31128298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
